The Ongoing Search for a Stratified Medicine Approach in Heart Failure⁎⁎Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.  by Tang, W.H. Wilson
T
f
A
W
C
T
l
s
(
p
A
a
t
a
f
c
s
o
a
d
c
b
a
h
d
s
t
g
o
r
t
b
p
I
d
a
l
t
fi
i
a
w
6
p
a
m
(
t
s
s
l
p
t
f
w
r
S
m
a
b
p
I
a
T
p
b
c
h
t
s
i
p
d
S
i
s
b
s
o
a
(
g
t
c
*
v
A
C
N
p
Journal of the American College of Cardiology Vol. 51, No. 24, 2008
© 2008 by the American College of Cardiology Foundation ISSN 0735-1097/08/$34.00
Published by Elsevier Inc. doi:10.1016/j.jacc.2008.02.069EDITORIAL COMMENT
he Ongoing Search
or a Stratified Medicine
pproach in Heart Failure*
. H. Wilson Tang, MD, FACC
leveland, Ohio
he mounting challenges to identify effective pharmaco-
ogic therapies for heart failure over the past decade have
purred the continued search for newer therapeutic targets
1). Oxidative stress has consistently been associated with
oor outcomes in heart failure and cardiac dysfunction.
nimal studies in this area have provided consistent mech-
nistic support for oxidative stress as a risk factor and
herapeutic target rather than a risk marker. However,
ssessing the degree of oxidative stress in patients with heart
ailure is challenging, because the pathophysiological pro-
esses that lead to it are highly complex.
See page 2301
There has been a longstanding recognition that elevated
erum uric acid (SUA) is a surrogate marker for xanthine
xidase activity and a marker of chronic inflammation. It is
lso associated with impaired diastolic performance, hemo-
ynamic alterations, and poorer outcomes in both acute and
hronic heart failure settings (2–5). Uric acid is a metabolic
yproduct of purine metabolism from xanthine oxidase
ctivity, and increased circulating levels in the setting of
eart failure may be due to either increased generation or
ecreased excretion. This scenario reflects only one of
everal mechanisms of reactive oxygen species generation
hat can lead to potential tissue damage and disease pro-
ression. Indeed, SUA levels of 9.5 mg/dl (or 565 mmol/l)
r above predicted mortality, and appeared synergistic with
educed left ventricular ejection fraction and peak ventila-
ory oxygen uptake in predicting 12-month mortality (6).
Inhibition of xanthine oxidase by allopurinol has also
een shown to improve endothelial function and clinical
resentation in several small-scale mechanistic studies (7,8).
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reviously received research support from Abbott Diagnostics, Inc.n addition, these observations are consistent with insights
erived from multivariable models of risk stratification such
s the Seattle Heart Failure Model, whereby both SUA
evels and allopurinol use were variables in the risk predic-
ion (9).
It is in this context that Hare et al. (10) reported their
ndings of a carefully conducted multicenter study in this
ssue of the Journal that examined the role of oxypurinol, the
ctive derivative of allopurinol, in symptomatic patients
ith heart failure. They found no overall difference between
months of oxypurinol and placebo in the percentage of
atients that improved, were unchanged, or worsened using
composite end point comprised of heart failure morbidity,
ortality, and quality of life. Fortunately, the OPT-CHF
Oxypurinol Therapy for Congestive Heart Failure) inves-
igators have the opportunity to pursue mechanistic under-
tanding of the potential of variations in treatment re-
ponses. They confirmed that subjects with elevated SUA
evels were associated with poorer outcomes, and with a
otential corresponding favorable response to oxypurinol in
his cohort.
The OPT-CHF investigators are to be congratulated
or completing an excellent trial and publishing their data
ith careful scrutiny of their results. There can be many
easons why this resulted in an overall neutral study.
ubjects in the oxypurinol group were older, had higher
ean brain natriuretic peptide levels (374 vs. 336 mg/dl),
nd shorter 6-min walk distance (257 vs. 278 m) at
aseline. Furthermore, despite a largely symptomatic
opulation (New York Heart Association functional class
II to IV, 6-min walk distance 267 m), the estimated
nnualized mortality rate was in the modest range of 8%.
his is most likely because this ambulatory patient
opulation was well treated (over 90% with evidence-
ased drug therapy) and in experienced heart failure
enters, and the authors have suggested that this may
ave potentially dampened the response to oxypurinol
herapy. The 6-month treatment duration was relatively
hort, but prior studies have also indicated improvement
n surrogate measures within similar or shorter time
eriods. The appropriateness of the study drug and its
osage can also play a role, although the reduction in
UA is reassuring.
In interpreting results of the OPT-CHF study, it is
mportant to recognize that conclusions based on the
ubjective clinical definitions of “benefit versus harm” may
e premature and may overlook the scientific foundations of
ound therapeutic concepts regarding the role of xanthine
xidase inhibition. Nevertheless, this hypothesis-generated
nalysis supported the broad concept of “stratified medicine”
11), whereby mechanism biomarkers can identify sub-
roups of patients with differential responses to a specific
herapy. This requires the ability to identify a biological
haracteristic (so-called “mechanism biomarker”) with the
otential to induce differential patient responses to a ther-
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June 17, 2008:2310–2 Editorial Commentpy. Also, there should be the need for multiple therapeutic
ptions that have sufficiently heterogeneous responses, and
he ability to link therapies to a subset of patients that are
ore likely to show that different response (11). This
oncept, although common in the treatment of other
iseases, such as infection or anemia, is infrequently adopted
n the contemporary management of heart failure, due to the
andate of evidence-based medicine and the “one-size fits
ll” clinical guidelines approach. Furthermore, there have
een many cases in cardiology whereby targeting a specific
echanism can yield to unanticipated adverse events, and
any of the current drugs do not provide a clearly defined,
echanistic understanding to demonstrate significant clin-
cal benefits. Therefore, the OPT-CHF investigators have
ade an important and bold step forward, supporting a
tratified medicine approach to heart failure management by
uggesting the possible role of SUA as a potential mecha-
ism biomarker.
The proposition made by the investigations, although
ttractive, is not without obvious challenges. The general
oncern is related to the mechanistic justification of the
pproach with the understanding of the beneficial results
o date. Proponents would argue that despite being a
ost-hoc (albeit pre-specified) analysis in this prospec-
ive, randomized, placebo-controlled trial, the reported
ifference is concordant between the improvement in
elf-reported quality-of-life measurements and the lower
eath rates with oxypurinol therapy in the subgroup.
ndeed, those who improve on average also have greater
ean reduction in natriuretic peptide levels than those
ith unchanged or worsening status. However, critics
ay point out that this subgroup represented a little bit
ore than one-third of the already small sample size, and
here were significant concerns regarding the observed
ncrease in heart failure hospitalization rates with oxy-
urinol in the high SUA subgroup. The discordance
etween the modest improvements in assigned changes in
ew York Heart Association functional class and marked
mprovements in patients’ self-perceived clinical status
aptured by the modified Packer score (the primary driver
f the “benefit” of oxypurinol use) were also disturbingly
roubling. Even when patients with advanced heart fail-
re may desire better quality than quantity of life, it is
qually important to have concordance of data all point-
ng in the same direction (or at least, neutral). In the end,
e are still dealing with potentially positive implications
rom overanalyzing relatively small subgroups with low
vent rates, hence with much room for error.
The reliability of SUA as a mechanism biomarker over
ime also needs further exploration. Clearly, xanthine
xidase inhibitors consistently lower SUA levels and
ther beneficial drugs that affect other pathways may not
 12). However, lowering SUA itself may simply be a
arker, and drugs independent of xanthine oxidase
nhibition may lower SUA without providing the per-
eived benefits (3 ). Furthermore, individual data-pointsf SUA in the placebo arm of the study illustrated
elatively large variability in serial measurements of SUA.
his may itself affect their reliability as surrogate mark-
rs. After all, the overall predictability of changes in SUA
ith changes in natriuretic peptide levels or clinical
vents was modest in this report. Other novel inflamma-
ory and oxidative stress markers have been suggested to
rovide important prognostic information in the heart
ailure population (13–15), but their potential as mech-
nism biomarkers have yet to be tested, since risk
rediction studies are largely inadequate for the demon-
tration of their clinical utility to guide therapy (16).
any of these concerns point to the need for prospective
alidation with larger sample sizes or longer-term follow-
p, most likely with the biomarker as a major inclusion
riterion.
Based on the results of the OPT-CHF study, the
uture of xanthine oxidase inhibition in the treatment of
eart failure remains unclear, but the relatively long-
tanding clinical safety profile with allopurinol and the
otential value of SUA testing can be an important
eassurance for future investigations. The logical next
tep is to pursue the next phase of clinical study to
xamine the effectiveness of xanthine oxidase inhibition
n patients with advanced heart failure and elevated SUA.
ut perhaps the most important lesson to be learned in
he OPT-CHF study is the proposal of stratified medi-
ine in heart failure—that we should not abandon such
aluable academic pursuits of identifying mechanism
iomarkers in therapeutic clinical trials, as they form the
asis of understanding the human pathophysiology and
efinement of treatment strategies.
eprint requests and correspondence: Dr. W. H. Wilson Tang,
ection of Heart Failure and Cardiac Transplantation Medicine,
eart and Vascular Institute, Cleveland Clinic, 9500 Euclid
venue, F25, Cleveland, Ohio 44195. E-mail: tangw@ccf.org.
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